Researcher
Marc Peeters
- Research Expertise (University of Antwerp):My expertise is in the field of oncology or cancer research. It is mainly focused on clinical translational research. This domain is very broad and ranges from bio-research to clinical studies
- Keywords (University of Antwerp):ONCOLOGY, Medicine
- Disciplines (Ghent University):Endocrinology and metabolic diseases, Paediatrics and neonatology, Nursing
- Disciplines (University of Antwerp):Cancer therapy, Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention
- Research techniques (University of Antwerp):Making protocols for studies. (Statistical) analysis of results
- Users of research expertise (University of Antwerp):Other researchers in the field. Students Pharma and Biotech companies
- See also: Marc Peeters (Ghent University)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Responsible
From1 Oct 2009 → 31 Dec 2018 - Department of Internal medicine (Department)
Member
From1 Oct 2000 → 30 Sep 2018
Projects
11 - 20 of 67
- Towards individualized treatment prediction and real-time follow-up of metastatic colorectal cancer patients using methylation biomarkers.From1 Nov 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Neuroendocrine neoplasmsFrom1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Investigation to reveal the immunerReaction upon COVID-vaccination in the Belgian cancer population: COVID protection and vaccine safety (REAL-V).From1 Oct 2021 → 30 Sep 2022Funding: Nonprofit institution or equivalents
- A novel photoelectrochemical detection technology for molecular cancer biomarkers.From1 Sep 2021 → 31 Oct 2022Funding: IOF - technology validation in lab
- Combining targeted therapy and immunotherapy to improve survival and quality of life of head and neck cancer patients.From1 Mar 2021 → TodayFunding: Nonprofit institution or equivalents
- Investigating drug repurposing and next-generation immune checkpoints to cure the incurable: novel strategies to treat pancreatic cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Rationally designed drug combination screen in more physiologically relevant in vitro organoid models: can we improve personalized therapy for pancreatic cancer?From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Improving colorectal cancer detection and treatment follow-up through the development of a novel methylation assay.From1 Nov 2020 → 31 Jul 2023Funding: Nonprofit institution or equivalents
- Screening and early detection of colorectal cancer and breast cancer in liquid biopsies using a newly-developed multi-regional methylation assay.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Rationally designed drug combination screen in more physiologically relevant in vitro organoid models: can we improve personalised therapy for pancreatic cancer?From1 Oct 2020 → TodayFunding: BOF - doctoral mandates
Publications
1 - 10 of 385
- Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from t(2024)
Authors: C.S. Karapetis, H. Liu, M.J. Sorich, L.D. Pederson, E. Van Cutsem, T. Maughan, J.Y. Douillard, C.J. O'Callaghan, D. Jonker, C. Bokemeyer, et al.
Pages: 1269 - 1278 - Bleeding and perforation complications after follow-up colonoscopies in faecal immunochemical test-based colorectal cancer screening(2024)
Authors: Thuy Ngan Tran, Joanna Bouchat, Marc Peeters, Bea Berghmans, Eric Van Cutsem, Guido Van Hal, Koen Van Herck, Sarah Hoeck
Pages: 26 - 48 - Hyperthermia in combination with emerging targeted and immunotherapies as a new approach in cancer treatment(2024)
Authors: Tine Logghe, Eke van Zwol, Benoit Immordino, Kris van den Cruys, Marc Peeters, Elisa Giovannetti, John-Paul Bogers
Pages: 1 - 35 - Auranofin repurposing for lung and pancreatic cancer(2024)
Authors: Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, et al.
Pages: 1 - 15 - Treatment of ambulatory patients with metastatic epidural spinal cord compression(2024)
Authors: Ruben Van den Brande, Dieter Thijs, Mark Bilsky, Marc Peeters
Pages: 175 - 184 - Relationship between health-related determinants and adherence to breast and colorectal cancer screening(2024)
Authors: Allegra Ferrari, Thuy Ngan Tran, Sarah Hoeck, Marc Peeters, Mathijs Goossens, Guido Van Hal
Pages: 347 - 353 - Increasing adherence to prophylactic swallowing exercises during head and neck radiotherapy(2023)
Authors: Margot Baudelet, Frederic Duprez, Leen Van den Steen, Sandra Nuyts, Ann Goeleven, Caroline Vandenbruaene, Hanne Massonet, Alice Vergauwen, Heleen Bollen, Sarah Deschuymer, et al.
Pages: 886 - 895 - A Belgian population-based study reveals subgroups of right-sided colorectal cancer with a better prognosis compared to left-sided cancer(2023)
Authors: Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Pages: e331 - e340 - Implementation of PROs in daily oncology care before and during the SARS-CoV-2 pandemic(2023)
Authors: Marika Rasschaert, Marc Peeters, Peter Van Dam, Annelies J R Janssens
Number of pages: 120 - New developments in treating RAS-mutated metastatic colorectal cancer(2023)
Authors: Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Pages: 965 - 987
Patents
1 - 6 of 6
- Combination immunotherapy of il-15 and cd40 agonist in cancer treatment (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation detection assay (Inventor)
- Methylation status of gasdermin E gene as cancer biomarker (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation status of gasdermin e gene as cancer biomarker (Inventor)